Patent ID: 7728002

Claim:
A method of treating a condition selected from the group consisting of atherosclerosis, myocardial infarction, hypertension and cerebral vascular disease in a subject, said method comprising activating PPAR receptors in said subject by administering to said subject an effective PPAR receptor activating amount of a pyrrolopyridine compound corresponding to formula I: wherein R 1 and R 2 each independently represent hydrogen, halogen, C 1 -C 3 alkyl, C 1 -C 4 alkoxy or CF 3 ; R 3 and R 4 each independently represent hydrogen or C 1 -C 4 alkyl; R represents hydrogen or C 1 -C 3 alkyl; n represents 1, 2 or 3; X represents a single bond or an oxygen atom, and Ar represents an aromatic or heteroaromatic nucleus selected from the group consisting of phenyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, furyl, thienyl, pyrrolyl, pyridyl, biphenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, quinolyl, isoquinolyl, 1,2,3,4-tetrahydroquinolyl, benzimidazolyl, benzopyrazinyl, indolyl, 2,3-dihydroindolyl, benzofuryl, 2,3-dihydrobenzofuryl, benzothiazolyl, benzothiadiazolyl, benzisoxazolyl, 3,4-dihydro-1,4-benzoxazinyl, 1,3-benzodioxolyl, 2,3-dihydrobenzodioxinyl, imidazothiazolyl and benzoxazolyl groups, optionally substituted with one or more substituents selected from the group consisting of halogen, C 1 -C 6 alkyl, C 1 -C 4 alkoxy, trifluoromethyl, trifluoromethoxy, nitro, acetyl, acetylamino, dialkylamino, amino, oxazolyl, thiazolyl, pyrazolyl, pyrrolidinyl, pyridyl, pyrimidinyl, methylpyrimidinyl and morpholinyl, or a pharmaceutically acceptable salt thereof.